EMV Capital (AIM:EMVC) CEO Dr Ilian Iliev talked with Proactive's Stephen Gunnion about the company's acquisition of assets from liquidated Destiny Pharma and how the move aligns with its broader investment strategy. Iliev explained that EMV Capital applied its 'Venture Build Program' to identify, acquire, and rebuild value in the XF-73 drug asset, which had shown promise in phase 2 clinical trials but had stalled before entering phase three. He said, "We are able to look at opportunities such as the former Destiny Pharma and look at how we can identify, acquire and rebuild value in incredibly valuable assets." The structure of the deal includes both upfront payments and deferred milestone-based components, aligning long-term incentives with outcomes such as regulatory progress and licensing opportunities. EMV Capital is now preparing to restart the phase 3 trial for XF-73, focusing on capital efficiency and low cash burn strategies. Iliev also highlighted the global potential of XF-73 in tackling antimicrobial resistance and hospital-acquired infections, noting that the US market alone includes over two million patients who could benefit. He confirmed that commercialisation plans will prioritise the US while also targeting emerging markets through partnerships and joint ventures. The company's capital-efficient model, he emphasised, enables scaling of high-impact opportunities without excessive dilution to shareholders. For more updates, visit Proactive's YouTube channel. Don’t forget to like the video, subscribe to the channel, and enable notifications to stay updated with our latest content. #EMVCapital #IlianIliev #ImpactInvesting #DestinyPharma #XF-73 #AntimicrobialResistance #HospitalInfections #PharmaInvestment #CapitalEfficiency #Phase3Trials #BiotechNews #HealthcareInnovation #EmergingMarkets